Analyst Allen Klee of Maxim Group reiterated a Buy rating on MCI Onehealth Technologies, Inc. Class A (AIDX – Research Report), reducing the price target to C$5.00.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Allen Klee has given his Buy rating due to a combination of factors, primarily focusing on MCI Onehealth Technologies’ significant revenue growth and strategic acquisitions. The company’s revenue for the fourth quarter of 2024 showed an impressive increase, largely driven by acquisitions and organic growth in demand for their software and AI solutions in healthcare.
Furthermore, the acquisition of segments from Orion Health and cost-cutting measures are expected to substantially boost revenue in the coming years. Despite a wider-than-expected adjusted EBITDA loss, the company’s future outlook remains positive with projected revenue growth and improved profitability. The decision to lower the price target is attributed to a higher share count, but the overall growth potential and strategic positioning in the healthcare IT sector support the Buy recommendation.
In another report released yesterday, Stifel Nicolaus also maintained a Buy rating on the stock with a C$3.80 price target.
AIDX’s price has also changed slightly for the past six months – from C$1.410 to C$1.500, which is a 6.38% increase.